高级检索
张煜, 严方, 肖易倍. VISTA靶点肿瘤免疫治疗的研究进展[J]. 中国药科大学学报, 2022, 53(4): 400-409. DOI: 10.11665/j.issn.1000-5048.20220403
引用本文: 张煜, 严方, 肖易倍. VISTA靶点肿瘤免疫治疗的研究进展[J]. 中国药科大学学报, 2022, 53(4): 400-409. DOI: 10.11665/j.issn.1000-5048.20220403
ZHANG Yu, YAN Fang, XIAO Yibei. Development of VISTA in tumor immunotherapy[J]. Journal of China Pharmaceutical University, 2022, 53(4): 400-409. DOI: 10.11665/j.issn.1000-5048.20220403
Citation: ZHANG Yu, YAN Fang, XIAO Yibei. Development of VISTA in tumor immunotherapy[J]. Journal of China Pharmaceutical University, 2022, 53(4): 400-409. DOI: 10.11665/j.issn.1000-5048.20220403

VISTA靶点肿瘤免疫治疗的研究进展

Development of VISTA in tumor immunotherapy

  • 摘要: T细胞激活抑制物免疫球蛋白可变区结构域(VISTA)是维持T细胞和髓系细胞稳态的B7家族成员。在体外和体内试验中,阻断VISTA能抑制肿瘤发展,是肿瘤联合免疫治疗的重要靶点。本文介绍了免疫检查点(ICIs)VISTA的结构特征以及在肿瘤微环境中的表达和生物学功能,总结了目前靶向VISTA的小分子抑制剂和中和抗体的最新研究现状,对目前的研究方法进行了讨论,旨在为VISTA后续研究和相关免疫检查点抗肿瘤药物研发提供理论参考。

     

    Abstract: V-domain immunoglobulin suppressor of T-cell activation (VISTA) is a member of the B7 family that maintains homeostasis in T cells and myeloid cells.Blocking VISTA inhibits tumor development in in vitro and in vivo trials, and is an important target for tumor immunotherapy.This review focuses on its structural features, expression and biological functions in tumor microenvironment, summarizes the current stage of small molecule inhibitors and antibodies targeting VISTA, and discusses the research approaches.It aims to provide a rationale for subsequent study on VISTA and the development of related immune checkpoint antitumor drugs.

     

/

返回文章
返回